Compare DDD & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DDD | OVID |
|---|---|---|
| Founded | 1986 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 343.2M | 365.5M |
| IPO Year | 2003 | 2017 |
| Metric | DDD | OVID |
|---|---|---|
| Price | $3.08 | $2.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $4.75 | $4.60 |
| AVG Volume (30 Days) | ★ 2.4M | 2.3M |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 109.79 | 3.90 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $386,902,000.00 | $7,252,000.00 |
| Revenue This Year | $2.48 | N/A |
| Revenue Next Year | $4.10 | $19.34 |
| P/E Ratio | $13.16 | ★ N/A |
| Revenue Growth | N/A | ★ 1181.27 |
| 52 Week Low | $1.48 | $0.27 |
| 52 Week High | $3.80 | $3.11 |
| Indicator | DDD | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 75.34 | 60.99 |
| Support Level | $1.86 | $2.56 |
| Resistance Level | $3.47 | $3.05 |
| Average True Range (ATR) | 0.20 | 0.16 |
| MACD | 0.06 | -0.02 |
| Stochastic Oscillator | 83.75 | 78.16 |
3D Systems Corp provide comprehensive 3D printing and digital manufacturing solutions, including 3D printers for plastics and metals, materials, software, and services, including maintenance, manufacturing and applications engineering. Its solutions support applications in two key industry verticals: Healthcare Solutions provide surgical planning, implants, instrumentation, and medical education solutions to help medical device manufacturers and healthcare providers accelerate, and ultimately, transform healthcare, and Industrial Solutions which includes aerospace, defense, transportation and general manufacturing. The company operates in the Americas, EMEA, and APAC regions.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.